|
DE2460304C2
(de)
|
1974-12-20 |
1983-08-04 |
Grünenthal GmbH, 5190 Stolberg |
1-n-Propyl-4-phthalimido-piperidin-2,6-dion, Verfahren zu seiner Herstellung und dieses enthaltende Arzneimittel
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US5510357A
(en)
|
1995-02-28 |
1996-04-23 |
Eli Lilly And Company |
Benzothiophene compounds as anti-estrogenic agents
|
|
DE122007000079I2
(de)
|
1996-07-24 |
2010-08-12 |
Celgene Corp |
Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
|
|
CA2287387C
(en)
|
1997-05-14 |
2010-02-16 |
Sloan-Kettering Institute For Cancer Research |
Methods and compositions for destruction of selected proteins
|
|
WO1999015521A1
(en)
|
1997-09-23 |
1999-04-01 |
Eli Lilly And Company |
Benzothiophenes
|
|
KR20010033248A
(ko)
|
1997-12-17 |
2001-04-25 |
폴락 돈나 엘. |
인테그린 수용체 길항제
|
|
JP2002523455A
(ja)
|
1998-08-31 |
2002-07-30 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体
|
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
|
EP1176959B1
(en)
|
1999-05-05 |
2006-03-08 |
Merck & Co., Inc. |
Novel prolines as antimicrobial agents
|
|
MXPA02012605A
(es)
|
2000-06-28 |
2003-05-14 |
Squibb Bristol Myers Co |
Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
WO2002020740A2
(en)
|
2000-09-08 |
2002-03-14 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
JP2005507363A
(ja)
|
2001-02-16 |
2005-03-17 |
イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー |
血管新生阻害トリペプチド、組成物およびそれらの使用方法
|
|
GB0106953D0
(en)
|
2001-03-20 |
2001-05-09 |
Univ Aberdeen |
Neufofibrillary labels
|
|
HN2002000136A
(es)
|
2001-06-11 |
2003-07-31 |
Basf Ag |
Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
|
|
US7030141B2
(en)
|
2001-11-29 |
2006-04-18 |
Christopher Franklin Bigge |
Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
|
|
CA2752124A1
(en)
|
2002-05-17 |
2003-11-27 |
Celgene Corporation |
Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
|
|
US20060004029A1
(en)
|
2002-08-30 |
2006-01-05 |
Akihiko Tsuruoka |
Nitrogen-containing aromatic derivatives
|
|
ATE458485T1
(de)
|
2003-07-11 |
2010-03-15 |
Proteologics Inc |
Ubiquitin-ligase-hemmer und verwandte verfahren
|
|
MXPA06015169A
(es)
|
2004-07-08 |
2007-08-21 |
Warner Lambert Co |
Moduladores de androgenos.
|
|
CN100383139C
(zh)
|
2005-04-07 |
2008-04-23 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
|
|
WO2006113942A2
(en)
|
2005-04-20 |
2006-10-26 |
Schering Corporation |
Method of inhibiting cathepsin activity
|
|
UA95244C2
(ru)
|
2005-06-22 |
2011-07-25 |
Плексикон, Инк. |
Соединения и способ модулирования активности киназ, и показания для их применения
|
|
UA91560C2
(ru)
|
2005-08-31 |
2010-08-10 |
Селджин Корпорэйшн |
Соединения ряда изоиндолимидов, их композиция и применение
|
|
AU2007226715A1
(en)
|
2006-03-03 |
2007-09-20 |
Novartis Ag |
N-formyl hydroxylamine compounds
|
|
WO2007127010A2
(en)
|
2006-03-29 |
2007-11-08 |
The Regents Of The University Of California |
Diarylthiohydantoin compounds
|
|
AU2007275415A1
(en)
|
2006-07-20 |
2008-01-24 |
Ligand Pharmaceuticals Incorporated |
Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation
|
|
RU2448101C2
(ru)
|
2006-08-30 |
2012-04-20 |
Селджин Корпорейшн |
5-замещенные изоиндолиновые соединения
|
|
CL2007002513A1
(es)
|
2006-08-30 |
2008-04-04 |
Celgene Corp Soc Organizada Ba |
Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
CA2668286C
(en)
|
2006-11-03 |
2014-09-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
|
JP2010515771A
(ja)
|
2007-01-16 |
2010-05-13 |
プロテオロジクス リミテッド |
トポイソメラーゼインヒビターの治療効果を増強する方法
|
|
US8415340B2
(en)
|
2007-07-25 |
2013-04-09 |
Bristol-Myers Squibb Company |
Triazine kinase inhibitors
|
|
MX2010001125A
(es)
|
2007-07-31 |
2010-09-30 |
Androscience Corp |
Composiciones incluyendo receptor androgeno de degradacion (ard) ponteciadores y metodos de tratamiento profilactico o terapeutico de trastornos de la piel y la caida de cabello.
|
|
KR101600634B1
(ko)
|
2007-12-28 |
2016-03-07 |
미쓰비시 타나베 파마 코퍼레이션 |
항암제
|
|
PT2358697E
(pt)
|
2008-10-29 |
2016-02-03 |
Celgene Corp |
Compostos de isoindolina para utilização no tratamento do cancro
|
|
US8691187B2
(en)
|
2009-03-23 |
2014-04-08 |
Eli Lilly And Company |
Imaging agents for detecting neurological disorders
|
|
WO2010141805A1
(en)
|
2009-06-05 |
2010-12-09 |
Janssen Pharmaceutica Nv |
Heterocyclic amides as modulators of trpa1
|
|
AU2010273220B2
(en)
|
2009-07-13 |
2015-10-15 |
President And Fellows Of Harvard College |
Bifunctional stapled polypeptides and uses thereof
|
|
PL3202460T3
(pl)
|
2010-02-11 |
2019-12-31 |
Celgene Corporation |
Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
|
|
US8198300B2
(en)
|
2010-04-29 |
2012-06-12 |
Universidad De Chile |
Method for preventing tau protein aggregation and treating Alzheimer's disease with a quinoline derivative compound
|
|
MX354217B
(es)
|
2010-05-14 |
2018-02-19 |
Dana Farber Cancer Inst Inc |
Composiciones y metodos para el tratamiento de leucemia.
|
|
PL2902030T3
(pl)
|
2010-05-14 |
2017-07-31 |
Dana-Farber Cancer Institute, Inc. |
Związki tienotriazolodiazepinowe do leczenia nowotworu
|
|
US20180144649A1
(en)
|
2010-06-07 |
2018-05-24 |
Affectiva, Inc. |
Smart toy interaction using image analysis
|
|
CN103153335A
(zh)
|
2010-06-30 |
2013-06-12 |
布兰代斯大学 |
小分子靶定的蛋白质降解
|
|
US8822520B2
(en)
|
2010-09-22 |
2014-09-02 |
Presidio Pharmaceuticals, Inc. |
Substituted bicyclic HCV inhibitors
|
|
WO2012040527A2
(en)
|
2010-09-24 |
2012-03-29 |
The Regents Of The University Of Michigan |
Deubiquitinase inhibitors and methods for use of the same
|
|
CN102477033A
(zh)
|
2010-11-23 |
2012-05-30 |
苏州波锐生物医药科技有限公司 |
苯并噻酚类化合物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途
|
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
|
CA2823837A1
(en)
|
2010-12-07 |
2012-06-14 |
Yale University |
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
|
|
WO2012090104A1
(en)
|
2010-12-31 |
2012-07-05 |
Kareus Therapeutics, Sa |
Methods and compositions for designing novel conjugate therapeutics
|
|
AU2012249491B2
(en)
|
2011-04-29 |
2016-12-15 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
PL2797888T3
(pl)
|
2011-12-31 |
2016-12-30 |
|
Połączone związki tricykliczne jako inhibitory kinazy raf
|
|
KR102668696B1
(ko)
|
2012-01-12 |
2024-05-29 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
|
US20150141470A1
(en)
|
2012-05-08 |
2015-05-21 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
WO2013170147A1
(en)
|
2012-05-11 |
2013-11-14 |
Yale University |
Compounds useful for promoting protein degradation and methods using same
|
|
AU2013283378B2
(en)
|
2012-06-25 |
2017-07-13 |
Oncoethix Gmbh |
Method of treating lymphoma using thienotriazolodiazepine compounds
|
|
WO2014015157A2
(en)
|
2012-07-19 |
2014-01-23 |
Philadelphia Health & Education Corporation |
Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
|
KR101738063B1
(ko)
|
2012-09-21 |
2017-05-19 |
아로그 파마슈티칼스, 인코퍼레이티드 |
구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
|
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
|
NL2011274C2
(en)
|
2013-08-06 |
2015-02-09 |
Illumicare Ip B V 51 |
Groundbreaking platform technology for specific binding to necrotic cells.
|
|
WO2014128111A1
(de)
|
2013-02-22 |
2014-08-28 |
Bayer Pharma Aktiengesellschaft |
4-substituierte pyrrolo- und pyrazolo-diazepine
|
|
US9492460B2
(en)
|
2013-02-27 |
2016-11-15 |
Bristol-Myers Squibb Company |
Carbazole compounds useful as bromodomain inhibitors
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
ES2648876T3
(es)
|
2013-07-23 |
2018-01-08 |
Bayer Pharma Aktiengesellschaft |
Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo
|
|
JP6542212B2
(ja)
|
2013-07-31 |
2019-07-10 |
ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． |
ブロモドメイン阻害剤としての新規キナゾリノン
|
|
US20150051208A1
(en)
|
2013-08-14 |
2015-02-19 |
Boehringer Ingelheim International Gmbh |
Pyridinones
|
|
US9428513B2
(en)
|
2013-11-07 |
2016-08-30 |
Boehringer Ingelheim International Gmbh |
Triazolopyrazine
|
|
CN110627770A
(zh)
|
2013-11-18 |
2019-12-31 |
福马疗法公司 |
作为bet溴域抑制剂的四氢喹啉组成物
|
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
|
US9458156B2
(en)
|
2014-12-23 |
2016-10-04 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
RU2738833C9
(ru)
|
2014-04-14 |
2022-02-28 |
Арвинас, Оперэйшнз, Инк. |
Имидные модуляторы протеолиза и способы их применения
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
|
JP6738326B2
(ja)
|
2014-06-06 |
2020-08-12 |
ザ スクリプス リサーチ インスティテュート |
フッ化硫黄（ｖｉ）化合物およびそれの製造方法
|
|
WO2015195863A1
(en)
|
2014-06-20 |
2015-12-23 |
Constellation Pharmaceuticals, Inc. |
Hydrated 2-((4s)-6-(4-chlorophenyl)-1 -methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
|
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
CA2960090A1
(en)
|
2014-10-02 |
2016-04-07 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Compound
|
|
KR20170068597A
(ko)
|
2014-10-27 |
2017-06-19 |
텐샤 세러퓨틱스 인코포레이티드 |
브로모도메인 저해제
|
|
WO2016097071A1
(en)
|
2014-12-18 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Estrogen receptor modulators and uses thereof
|
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
GB201504314D0
(en)
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
|
EP3270917A4
(en)
|
2015-03-18 |
2018-08-08 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201506872D0
(en)
|
2015-04-22 |
2015-06-03 |
Ge Oil & Gas Uk Ltd |
Novel compounds
|
|
CA2988414C
(en)
|
2015-06-04 |
2023-09-26 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
BR112017028269A2
(pt)
|
2015-07-13 |
2018-09-04 |
Arvinas Inc |
composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
GB201516243D0
(en)
|
2015-09-14 |
2015-10-28 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
BR112018068906A2
(pt)
|
2016-03-16 |
2019-01-22 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
SG11201808728QA
(en)
|
2016-04-06 |
2018-11-29 |
Univ Michigan Regents |
Mdm2 protein degraders
|
|
AU2017254713C1
(en)
|
2016-04-22 |
2021-04-29 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for degradation of EGFR and methods of use
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US20180072711A1
(en)
|
2016-09-15 |
2018-03-15 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
CN110506039A
(zh)
*
|
2016-10-11 |
2019-11-26 |
阿尔维纳斯股份有限公司 |
用于雄激素受体靶向降解的化合物和方法
|
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
WO2018098280A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
|
|
BR112019011200B1
(pt)
|
2016-12-01 |
2021-12-28 |
Arvinas Operations, Inc |
Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
|
|
KR20250117470A
(ko)
|
2016-12-23 |
2025-08-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
|
JP2020505327A
(ja)
|
2016-12-23 |
2020-02-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
BR112019015312A2
(pt)
|
2017-01-26 |
2020-03-10 |
Arvinas Operations, Inc. |
Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
|
|
IL312367A
(en)
*
|
2017-01-31 |
2024-06-01 |
Arvinas Operations Inc |
Cereblon ligands and bifunctional compounds comprising the same
|
|
AU2018258581A1
(en)
|
2017-04-28 |
2019-11-07 |
Quartz Therapeutics, Inc. |
RAF-degrading conjugate compounds
|
|
WO2018204422A1
(en)
|
2017-05-01 |
2018-11-08 |
Spg Therapeutics, Inc. |
Tripartite androgen receptor eliminators, methods and uses thereof
|
|
WO2019079701A1
(en)
*
|
2017-10-20 |
2019-04-25 |
Dana-Farber Cancer Institute, Inc. |
HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE
|
|
WO2019148055A1
(en)
|
2018-01-26 |
2019-08-01 |
Yale University |
Imide-based modulators of proteolysis and methods of use
|
|
FI3904350T3
(fi)
|
2018-04-12 |
2023-11-15 |
Bayer Ag |
N-(syklopropyylimetyyli)-5-(metyylisulfonyyli)-n-{1-[1-(pyrimidin-2-yyli)-1h-1,2,4-triatsol-5-yyli]etyyli}bentsamidijohdannaisia ja vastaavia pyridiinikarboksamidijohdannaisia tuholaistorjunta-aineina
|
|
IL302595A
(en)
*
|
2018-04-13 |
2023-07-01 |
Arvinas Operations Inc |
Servalon ligands and bifunctional compounds containing them
|
|
CN110746399B
(zh)
|
2018-07-23 |
2022-04-22 |
上海美志医药科技有限公司 |
具有降解雄激素受体活性的化合物
|
|
CN113473987B
(zh)
|
2018-12-19 |
2024-09-03 |
细胞基因公司 |
被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
|
|
CN113453681B
(zh)
|
2018-12-19 |
2024-10-11 |
细胞基因公司 |
经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
EP3917916A4
(en)
|
2019-01-30 |
2022-12-14 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
US11547759B2
(en)
|
2019-01-30 |
2023-01-10 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
WO2020198712A1
(en)
|
2019-03-28 |
2020-10-01 |
Essa Pharma, Inc. |
Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
|
|
CN114269331A
(zh)
|
2019-03-28 |
2022-04-01 |
埃萨制药股份有限公司 |
雄激素受体调节剂和用作蛋白水解靶向嵌合体配体的方法
|
|
US12331061B2
(en)
|
2019-04-18 |
2025-06-17 |
Accutar Biotechnology Inc. |
Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereof
|
|
EP3971176A4
(en)
|
2019-05-17 |
2023-01-25 |
Hinova Pharmaceuticals Inc. |
AR AND BET AROMATIC AMINE TARGETING PROTEIN DEGRADATION CHIMERIC COMPOUND AND USE THEREOF
|
|
CN112457366B
(zh)
|
2019-09-06 |
2024-03-19 |
江西济民可信集团有限公司 |
作为蛋白降解剂的并环类化合物及其制备方法和应用
|
|
WO2021055756A1
(en)
|
2019-09-19 |
2021-03-25 |
The Regents Of The University Of Michigan |
Spirocyclic androgen receptor protein degraders
|
|
JP7307796B2
(ja)
|
2019-09-23 |
2023-07-12 |
アキュター バイオテクノロジー インコーポレイテッド |
アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用
|
|
EP4034114A4
(en)
|
2019-09-23 |
2023-07-26 |
Accutar Biotechnology Inc. |
NEW UREAES HAVING ANDROGEN RECEPTOR DEGRADING ACTIVITY AND THEIR USES
|
|
WO2021061644A1
(en)
|
2019-09-23 |
2021-04-01 |
Accutar Biotechnology Inc. |
Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
|
|
IL293962B2
(en)
|
2019-12-19 |
2025-10-01 |
Jacobio Pharmaceuticals Co Ltd |
Mutant KRAS protein inhibitors
|
|
AU2020405129A1
(en)
|
2019-12-19 |
2022-06-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
TW202525813A
(zh)
|
2019-12-19 |
2025-07-01 |
比利時商健生藥品公司 |
經取代之直鏈螺環接衍生物
|
|
BR112022011237A2
(pt)
|
2019-12-19 |
2022-08-30 |
Bayer Ag |
Derivados de furoindazol
|
|
IL293980B1
(en)
|
2019-12-19 |
2026-04-01 |
Debiopharm Int Sa |
New compounds and their use
|
|
KR20220119066A
(ko)
|
2019-12-19 |
2022-08-26 |
스키노시브 |
접착성 광보호성 화합물 및 이의 용도
|
|
CN114829342A
(zh)
|
2019-12-23 |
2022-07-29 |
上海济煜医药科技有限公司 |
一种蛋白降解剂化合物的制备方法和应用
|
|
PE20221283A1
(es)
|
2019-12-27 |
2022-09-05 |
Lupin Ltd |
Compuestos triciclicos sustituidos
|
|
CN113582974B
(zh)
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
EP4157230A1
(en)
|
2020-05-29 |
2023-04-05 |
Blueprint Medicines Corporation |
Pralsetinib pharmaceutical compositions
|
|
KR20230028268A
(ko)
|
2020-05-29 |
2023-02-28 |
뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 |
구충성 헤테로시클릭 화합물
|
|
CR20230007A
(es)
|
2020-06-12 |
2023-06-01 |
Shanghai Jemincare Pharmaceuticals Co Ltd |
Compuesto de ftalazinona, y método de preparación y uso médico de este.
|
|
KR20230027066A
(ko)
|
2020-06-24 |
2023-02-27 |
셀진 코포레이션 |
세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
|
|
JP7778095B2
(ja)
|
2020-06-24 |
2025-12-01 |
セルジーン コーポレーション |
セレブロン結合化合物、その組成物及びそれによる治療方法
|
|
KR20230027214A
(ko)
|
2020-06-24 |
2023-02-27 |
셀진 코포레이션 |
세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
|
|
CN117327059A
(zh)
|
2020-07-08 |
2024-01-02 |
北京泰德制药股份有限公司 |
抑制并诱导蛋白降解的化合物
|
|
WO2022048605A1
(zh)
|
2020-09-04 |
2022-03-10 |
南昌奥瑞药业有限公司 |
一种杂环化合物、其制备方法、中间体、组合物以及应用
|
|
CN114163444B
(zh)
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
CN116529248B
(zh)
|
2020-11-25 |
2025-10-17 |
西藏海思科制药有限公司 |
一种苯环衍生物及其组合物和药学上的应用
|
|
JP2023552818A
(ja)
|
2020-12-11 |
2023-12-19 |
アルビナス・オペレーションズ・インコーポレイテッド |
前立腺癌を治療する方法
|
|
US11957696B2
(en)
|
2021-02-15 |
2024-04-16 |
Propella Therapeutics, Inc. |
Abiraterone prodrugs
|
|
JP2026500894A
(ja)
|
2022-10-24 |
2026-01-09 |
アルヴィナス・オペレーションズ・インコーポレイテッド |
アンドロゲン受容体の標的分解のための化合物及び方法
|
|
CN121079292A
(zh)
|
2023-03-30 |
2025-12-05 |
阿维纳斯企业公司 |
用于靶向降解雄激素受体的化合物的结晶形式
|